<DOC>
	<DOCNO>NCT01031069</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . This Phase IV , observer-blind study design evaluate safety immunogenicity Cervarix™ HIV infect female age 15 25 year compare Merck 's HPV vaccine ( Gardasil® ) . For comparative purpose , group HIV negative female also evaluate . All subject receive HPV vaccine ( either Cervarix™ Gardasil® ) accord three-dose schedule ( Day 0 , Week 6 , Month 6 ) .</brief_summary>
	<brief_title>Evaluation Safety Immunogenicity Human Papillomavirus ( HPV ) Vaccine Human Immunodeficiency Virus ( HIV ) Infected Females</brief_title>
	<detailed_description>This Protocol summary update follow Protocol Amendment 7 , December 2013 , follow : • Addition new EU country , change assay assay cut-off enrollment additional subject clarify activity protocol mandatory HIV+ subject .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parent ( ) /legally acceptable representative ( ) ( LAR ) comply requirement protocol . A female , include , 15 25 year age time first vaccination . Written inform consent obtain subject and/or subject 's parent LAR . Subjects willing undergo HIV Voluntary Counseling Testing ( VCT ) willing inform HIV infection status . For HIV seropositive subject : Subjects must HIV seropositive accord World Health Organization ( WHO ) case definition . Subject must asymptomatic ( persistent generalize lymphadenopathy ) . Subjects CD4 cell count &gt; 350 cells/mm3 . If currently take antiretrovirals ( ARVs ) , subject must compliant triple therapy ( highly active ART ) undetectable viral load two previous clinical visit within six month prior study entry . For HIV seronegative subject : Subjects confirm HIV seronegative screening visit . For nonvirgin female subject : Subjects must history abnormal cytology CIN 1/2/3 . Subjects must six lifetime sexual partner prior enrollment . Subjects must history congenital malformation uterine cervix , history cauterization surgical procedure involve damage transformation zone cervix stenosis . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test screen day vaccination , agree continue adequate contraception entire treatment period two month completion vaccination series . Previous vaccination HPV , plan administration HPV vaccine foreseen study protocol study period ( Day 0 Month 24 ) . ART compliant National Guidelines . Active tuberculosis ( TB ) visit ( criteria mandatory HIV+ subject ) . Current TB therapy . Hemoglobin &lt; 8.0 g/dL screen visit . Creatinine &gt; 1.5fold upper limit normal ( ULN ) screen visit . Alanine aminotransferase ( ALT ) &gt; 2.5fold ULN screen visit . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period ( Day 0 Month 24 ) . Chronic administration ( define 14 consecutive day ) immunosuppressant immunemodifying drug ( exception ART ) within six month prior first vaccine dose . Administration vaccine foreseen study protocol within 30 day ( Days 0 29 ) first dose study vaccine/control . Enrollment postpone subject outside specify window . Planned administration vaccine foreseen study protocol within 30 day 30 day ( i.e. , Days 0 29 ) dose study vaccine . Previous administration component investigational vaccine . Cancer autoimmune disease treatment . Hypersensitivity latex . History allergic disease reaction likely exacerbate component vaccine/control . Acute disease and/or fever time enrollment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory test perform screen visit . History neurological disorder seizure . Pregnant breastfeed female . A subject planning become pregnant , likely become pregnant ( determined investigator ) planning discontinue contraceptive precaution study period , two month last vaccine dose ( i.e. , Month 8 ) . Concurrently participate another clinical study , time study period ( Day 0 Month 24 ) , subject expose investigational noninvestigational product . Any medically diagnose suspected immunodeficient condition ( HIV HIV seropositive subject ) , base medical history , physical examination and/or laboratory test result . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine/control plan administration study period . Enrollment postpone subject outside specify window . Administration trimethoprim/sulphamethoxazole within seven day first dose study vaccine/control , plan administration trimethoprim/sulphamethoxazole within seven day first dose study vaccine/control . Current drug alcohol abuse . Child care .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cervarix</keyword>
	<keyword>Gardasil</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Safety</keyword>
	<keyword>HPV vaccine</keyword>
</DOC>